Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: FX006 Clear all

Conditions: Osteoarthritis of the Knee
Interventions: FX006 10 mg, FX006 40 mg, TCA IR 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Paducah, Kentucky • Duncansville, Pennsylvania • Dallas, Texas

Conditions: Osteoarthritis, Hip
Interventions: FX006, Normal saline; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 27 more

Conditions: Osteoarthritis, Hip
Interventions: FX006 32 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Tucson, Arizona • Canoga Park, California • La Mesa, California + 2 more

Conditions: Osteoarthritis of the Shoulder, Osteoarthritis of the Hip
Interventions: FX006 32 mg, TAcs 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: El Cajon, California • La Mesa, California • San Diego, California + 3 more

Conditions: Osteoarthritis, Knee
Interventions: FX006 32 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: El Cajon, California • La Mesa, California • Pomona, California + 5 more

Conditions: Bilateral Knee Osteoarthritis
Interventions: FX006 32 mg, TAcs 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Torrance, California • Rochester, New York • Duncansville, Pennsylvania

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg, TCA IR 40; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Canoga Park, California • San Diego, California • Hialeah, Florida + 1 more

Conditions: Trochanteric Bursitis
Interventions: FX006; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Knee Osteoarthritis
Interventions: Zilretta; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Post-traumatic Osteoarthritis of the Knee
Interventions: FX006 32 mg, TCA IR 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Osteoarthritis of the Knee
Interventions: FX006, Placebo, TCA IR 40; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more

Conditions: Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Interventions: FX006 32 mg, TCA IR 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 8
States / cities: Anaheim, California • El Cajon, California • North Hollywood, California + 5 more

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Tucson, Arizona • Anaheim, California • Canoga Park, California + 14 more

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg, Placebo, FX006 16 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 39
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 36 more

Conditions: Osteoarthritis of the Shoulder, Adhesive Capsulitis
Interventions: FX006, Normal Saline; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more

Conditions: Osteoarthritis of the Knee
Interventions: FX006, TCA IR; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Tucson, Arizona • Duncansville, Pennsylvania

Conditions: Rotator Cuff Tears, Rotator Cuff Tendinitis, Rotator Cuff Impingement, Injections, Glucocorticoids
Interventions: FX006 Injection; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 40 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Great Neck, New York

Search by objective public record fields.

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis

The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA

Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

Study of FX006 in Patients With Osteoarthritis of the Knee

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease